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below the 70th percentile and 1 (poor adherence) if above the 70th percentile. ABR 
was also dichotomized into no bleeds (0 ABR), the true goal of prophylaxis, versus 
1 or more bleeds (1+ ABR). Results: Reported ABR ranged from 0 to 54 (median 
1). There was not a significant relationship between VERITAS-Pro score and ABR. 
There was a significantly greater percentage of patients experiencing one or more 
bleeds in the VERITAS-Pro poor adherence group (86%) than in the VERITAS-Pro good 
adherence group (62%). ConClusions: VERITAS-Pro scores reflecting adherence 
are significant predictors of ABR; individuals with poor adherence on the VERITAS-
Pro are more likely to have at least 1 bleed per year versus those with good adher-
ence. However, the high percentage of patients experiencing one or more bleeds in 
both groups indicates that factors other than adherence may impact annualized 
bleed rates.
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objeCtives: For people with hemophilia A, factor VIII (FVIII) prophylaxis is 
burdensome, potentially leading to poor compliance. Treatment adherence and 
outcomes may be improved with drugs requiring less frequent infusions. In the 
absence of head-to-head direct comparative evidence from clinical trials, this 
analysis indirectly compared the prophylactic efficacy of recombinant FVIII Fc 
fusion protein (rFVIIIFc) with the published results of current rFVIII products and 
simulated effects of potential differences in real-world compliance between regi-
mens. Methods: rFVIIIFc and rFVIII were indirectly compared using data from 
previously treated subjects in the A-LONG phase 3 study (rFVIIIFc; individualized 
arm) and published clinical studies of routine prophylaxis (rFVIII; identified by lit-
erature search). Efficacy was compared using reported differences in mean annual-
ized bleed rates (ABRs) for individual and pooled results using meta-analysis with 
random effects. Unreported standard deviations of ABR were estimated assuming 
a Poisson distribution and adjusted for over-dispersion. A model was developed to 
assess the effect of compliance changes on ABR. Results: This analysis included 
published results from the A-LONG study (severe hemophilia; rFVIIIFc; Mahlangu 
2013) and 4 studies of rFVIII (moderate/severe hemophilia; Advate®: Tarantino 
2004, Shapiro 2003, and Valentino 2012; Xyntha®: Recht 2009). Infusion frequencies 
were 1.4-2.4 (median 2.0) times/week for rFVIIIFc and 2.3-4 times/week for rFVIII. 
Mean ABR for rFVIIIFc was 2.9; the pooled mean ABR estimate for rFVIII was 4.8 
(I2 = 44.2%, Δ ABR= 1.8; P= 0.003). Simulations showed that statistically significant 
improvements in mean ABR would result from improving compliance with rFVIIIFc 
by ≥ 6-12 percentage points. CONCLUSIONSResults of this unadjusted indirect 
comparison of clinical studies suggest that routine prophylaxis with rFVIIIFc may 
result in a lower mean ABR than that of other rFVIII products examined. Moreover, 
potential improvements in compliance associated with less burdensome dosing 
requirements, as suggested by studies in other chronic diseases, may result in 
better effectiveness with rFVIIIFc.
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objeCtives: Hemophilia B prophylaxis with factor IX (FIX) requires frequent infu-
sions, potentially leading to poor compliance and reduced therapeutic effectiveness. 
In the absence of head-to-head direct comparative evidence from clinical trials, this 
analysis indirectly compared the prophylactic efficacy of recombinant FIX Fc fusion 
protein (rFIXFc) and other rFIX products, which require more frequent infusions. 
Additionally, we simulated the effects of potential differences in real-world com-
pliance between regimens. Methods: rFIXFc and rFIX were indirectly compared 
using data from clinical trials of previously treated subjects administered rFIXFc 
(B-LONG phase 3 study, weekly prophylaxis arm) or rFIX (published clinical stud-
ies of routine prophylaxis identified by literature search). Efficacy was compared 
using reported differences in mean annualized bleed rates (ABRs) for individual 
and pooled results using meta-analysis with random effects. Unreported standard 
deviations of ABR were estimated assuming a Poisson distribution and adjusted for 
over-dispersion. A model simulating the effect of improved compliance on ABR was 
developed. Results: This analysis included results from the published B-LONG 
study (severe hemophilia; rFIXFc; Powell 2013) and 4 published studies of rFIX (mod-
erate/severe hemophilia; BeneFIX®: Roth 2001, Lambert 2007, and Korth-Bradley 
2011; Rixubis®: Windyga 2012). Infusion frequencies were once weekly for rFIXFc, 
and 1 to > 3 times/week (Roth 2001, Lambert 2007) or 1-2 times/week (Korth-Bradley 
2011, Windyga 2012) for rFIX. Mean ABR for rFIXFc was 3.07; the pooled mean ABR 
estimate for rFIX was 3.84 based on these clinical studies (I2= 57.5%, Δ ABR= 0.77; 
P= 0.23). Simulations showed that statistically significant improvements in mean 
ABR would result from improving compliance with rFIXFc by ≥ 9-14 percentage 
points. ConClusions: Based on simulations of potential differences in real-world 
compliance, less burdensome dosing with rFIXFc may lead to improved real-world 
effectiveness, consistent with findings in other chronic diseases.
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objeCtives: The purpose of this analysis is to examine hospital-based utilization 
in Wegener’s granulomatosis (WG), a form of autoimmune disease characterized 
by necrotizing granulomas and vasculitis affecting approximately 3 out of every 
100,000 people in the US. Methods: A retrospective cross-sectional analysis exam-
ined inpatient (N= 7,202) and outpatient visits (N= 24,971) in the MedAssets health 
system data from 2009 to 2013. In addition to patient and hospital characteristics, 
the Charlson comorbidity index and its individual comorbidities were evaluated. 
Analysis of prevalent procedures and their comparative effects on utilization were 
explored. Measures of utilization included number of visits and length of stay (LOS). 
Negative-binomial multivariate regression was used to identify significant LOS driv-
ers. Results: Hospital utilization was primarily for outpatient services (77.6%) with 
a mean of 2.5 outpatient visits per patient. The primary diagnosis was WG for 58.6% 
of outpatients and16.6% of inpatients. Other common inpatient diagnoses included 
pneumonia (5.2%), septicemia (3.5%), and acute renal failure (3.4%). The sample 
included more females (54.6%) than males (45.3%) and 56.8% was between 40 and 
69 years old. The mean Charlson score was 2.11 with renal disease (37.4%), chronic 
pulmonary disease (27.2%), diabetes (18.9%), congestive heart failure (11.1%), and 
rheumatic disease (10%) as the most prevalent comorbidities. The most common 
inpatient procedures were hemodialysis (26.3%), packed cell transfusions (18.0%), 
closed bronchial biopsy (8.1%), and closed renal biopsy (6.5%). Average LOS was 
8.4 days. The most significant drivers associated with longer LOS included bron-
chial (IRR= 1.72, p< .0001) and renal (IRR= 1.48, p< .0001) biopsy procedures, packed 
cell transfusions (IRR= 1.41 ,p< .0001), and therapeutic plasmapheresis (IRR= 1.34, 
p< .0001). ConClusions: Although a rare disease WG patients consume signifi-
cant amounts of health care resources in the hospital setting. Primary utilization 
occurs in the outpatient setting, however, when hospitalized LOS is often lengthy. 
Further research is required to understand the effect of interventions/treatments 
on mitigating progress of this disease.
SYStemIc dISorderS/condItIonS – Patient-reported outcomes & Patient 
Preference Studies
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objeCtives: Fibromyalgia is a disorder characterized by widespread chronic mus-
culoskeletal pain. This study aims to understand the treatment patterns associated 
with currently available and commonly used medications in the management of 
fibromyalgia. Methods: This retrospective study used the MarketScan claim data-
base to identify patients who had a first fibromyalgia diagnosis code (ICD-9-CM: 
729.1) in 2009-2011 with a repeat diagnosis within a year; were at least 18 years old; 
and had continuous enrollment for ≥ 12 months before and after the date of first 
diagnosis, i.e. the index date. The pain treatments assessed were: anticonvulsants 
(pregabalin, gabapentin), antidepressants (amitriptyline, cyclobenzaprine, venlafax-
ine, duloxetine, milnacipran), and opioid (tramadol). Adherence was evaluated using 
percent of days covered (PDC) and categorized into low (< 50%), medium (50%-80%), 
and high (≥ 80%). The 1-year discontinuation (defined as the first drug supply gap 
≥ 90 days) rate was estimated using Kaplan-Meier curve. Results: A total of 240,144 
patients met the inclusion criteria; 68% were female and the study sample mean 
(SD) age was 48 (13.8) years. Only 31% (N= 74,738) of the patients initiated a treatment 
of interest within a year after the index date. The 3 most frequently dispensed ones 
were cyclobenaprine (27.4%), tramadol (17.9%), and gabapentin (16.3%). Duloxetine, 
pregabalin, and milnacipran accounted for 13.6%, 8.9%, and 3.8% of treated patients 
respectively. Adherence was suboptimal for all of these treatments: mean PDCs (% 
with high adherence) were 59% (39%), 47% (24%), 44% (22%), 43% (21%), 27% (9%), 
and 20% (5%) for duloxetine, pregabalin, gabapentin, milnacipran, tramadol, and 
cyclobenaprine, respectively; and the corresponding 1-year discontinuation rates 
were 52%, 65%, 67%, 72%, 80%, and 90%, respectively. ConClusions: The major-
ity of patients diagnosed with fibromyalgia were not treated with the assessed 
therapies in this study cohort. Adherence and persistence with the current pain 
medications were sub-optimal.
PSY39
adherence to ProPhYlactIc treatment In hemoPhIlIa aS meaSured 
uSIng the VerItaS-Pro and annual bleed rate (abr)
Duncan NA1, Kronenberger WG2, Krishnan S3, Shapiro AD1
1Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA, 2Indiana University, 
Indianapolis, IN, USA, 3Biogen Idec, Cambridge, MA, USA
objeCtives: Few studies exist to support the hypothesis that nonadherence to 
prophylactic treatment of hemophilia leads to increased bleeding. The VERITAS-Pro, 
a validated measure of adherence to prophylaxis, allows objective measurement of 
the relationship between adherence and patient outcomes. The study objective was 
to correlate VERITAS-Pro scores and annual bleed rate (ABR), defined as the number 
of bleeds a patient has in a given year. Methods: The study sample was comprised 
of patients utilizing prophylaxis treatment who completed the VERITAS-Pro for the 
validation study published by Duncan et al in Haemophilia in 2007 (n= 66). ABR was 
extrapolated from patient infusion logs and, for those patients with incomplete or 
missing logs, from electronic medical records. Pearson and Spearman correlational 
analyses were run between VERITAS-Pro scores and ABR. A cutoff analysis was 
done in which the 70th percentile was chosen as a clinically useful cutoff score 
and VERITAS-Pro scores were dichotomized and coded as 0 (good adherence) if 
